CoChat
Sign Up
Cited by 160RNA Interference and Gene DeliveryBarrier Structure and Function StudiesNanoparticle-Based Drug Delivery

BBB pathophysiology–independent delivery of siRNA in traumatic brain injury

Open access
Li, Wen, Qiu, Jianhua, Li, Xiang-Ling, Aday, Sezin, Zhang, Jingdong, Conley, Grace, Xu, Jun, Joseph, John +5 more·2021·Science Advances
DOI 10.1126/sciadv.abd6889PMC PMC7775748

Published version of a preprint

Open this paper in CoChat — free account

Abstract

We describe a nanoparticle platform for brain delivery of nucleic acid–based therapeutics to treat TBI.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.abd6889

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 49

  1. [1]Roozenbeek B., Maas A. I. R., Menon D. K., Changing patterns in the epidemiology of traumatic brain injury. Nat. Rev. Neurol. 9, 231– 236 (2013). 23443846
  2. [4]Goldstein L. E., Fisher A. M., Tagge C. A., Zhang X.-L., Velisek L., Sullivan J. A., Upreti C., Kracht J. M., Ericsson M., Wojnarowicz M. W., Goletiani C. J., Maglakelidze G. M., Casey N., Moncaster J. A., Minaeva O., Moir R. D., Nowinski C. J., Stern R. A., Cantu R. C., Geiling J., Blusztajn J. K., Wolozin B. L., Ikezu T., Stein T. D., Budson A. E., Kowall N. W., Chargin D., Sharon A., Saman S., Hall G. F., Moss W. C., Cleveland R. O., Tanzi R. E., Stanton P. K., McKee A. C., Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci. Transl. Med. 4, 134ra160 (2012). PMC3739428 22593173
  3. [5]McKee A. C., Stein D., Nowinski C. J., Stern R. A., Daneshvar D. H., Alvarez V. E., Lee H.-S., Hall G., Wojtowicz S. M., Baugh C. M., Riley D. O., Kubilus C. A., Cormier K. A., Jacobs M. A., Martin B. R., Abraham C. R., Ikezu T., Reichard R. R., Wolozin B. L., Budson A. E., Goldstein L. E., Kowall N. W., Cantu R. C., The spectrum of disease in chronic traumatic encephalopathy. Brain 136, 43– 64 (2013). 23208308 PMC3624697
  4. [6]Smith D. H., Johnson V. E., Stewart W., Chronic neuropathologies of single and repetitive TBI: Substrates of dementia? Nat. Rev. Neurol. 9, 211– 221 (2013). 23458973 PMC4513655
  5. [7]DeKosky S. T., Blennow K., Ikonomovic M. D., Gandy S., Acute and chronic traumatic encephalopathies: Pathogenesis and biomarkers. Nat. Rev. Neurol. 9, 192– 200 (2013). 23558985 PMC4006940
  6. [8]Blennow K., Hardy J., Zetterberg H., The neuropathology and neurobiology of traumatic brain injury. Neuron 76, 886– 899 (2012). 23217738
  7. [9]Sharp D. J., Scott G., Leech R., Network dysfunction after traumatic brain injury. Nat. Rev. Neurol. 10, 156– 166 (2014). 24514870
  8. [10]Yoo D., Magsam A. W., Kelly A. M., Stayton P. S., Kievit F. M., Convertine A. J., Core-cross-linked nanoparticles reduce neuroinflammation and improve outcome in a mouse model of traumatic brain injury. ACS Nano 11, 8600– 8611 (2017). 28783305 PMC10041566
  9. [14]Kwon E. J., Skalak M., Bu R. L., Bhatia S. N., Neuron-targeted nanoparticle for siRNA delivery to traumatic brain injuries. ACS Nano 10, 7926– 7933 (2016). 27429164 PMC5896006
  10. [15]Kang J., Joo J., Kwon E. J., Skalak M., Hussain S., She Z.-G., Ruoslahti E., Bhatia S. N., Sailor M. J., Self-sealing porous silicon-calcium silicate core–shell nanoparticles for targeted siRNA delivery to the injured brain. Adv. Mater. 28, 7962– 7969 (2016). 27383373 PMC6274592
  11. [16]Bharadwaj V. N., Lifshitz J., Adelson P. D., Kodibagkar V. D., Stabenfeldt S. E., Temporal assessment of nanoparticle accumulation after experimental brain injury: Effect of particle size. Sci. Rep. 6, 29988 (2016). 27444615 PMC4957235
  12. [17]Xiong Y., Mahmood A., Chopp M., Animal models of traumatic brain injury. Nat. Rev. Neurosci. 14, 128– 142 (2013). 23329160 PMC3951995
  13. [18]Chodobski A., Zink B. J., Szmydynger-Chodobska J., Blood-brain barrier pathophysiology in traumatic brain injury. Transl. Stroke Res. 2, 492– 516 (2011). 22299022 PMC3268209
  14. [19]Kuriakose M., Rao K. V. R., Younger D., Chandra N., Temporal and spatial effects of blast overpressure on blood-brain barrier permeability in traumatic brain injury. Sci. Rep. 8, 8681 (2018). 29875451 PMC5989233
  15. [20]Sahyouni R., Gutierrez P., Gold E., Robertson R. T., Cummings B. J., Effects of concussion on the blood–brain barrier in humans and rodents. J. Concussion. 1, 10.1177/2059700216684518, (2017). PMC6391889 30828466 · DOI
  16. [21]Nowak M., Helgeson M. E., Mitragotri S., Delivery of nanoparticles and macromolecules across the blood brain barrier. Adv. Therap. 3, 1900073 (2019).
  17. [22]Furtado D., Björnmalm M., Ayton S., Bush A. I., Kempe K., Caruso F., Overcoming the blood–brain barrier: The role of nanomaterials in treating neurological diseases. Adv. Mater. 30, 1801362 (2018). 30066406
  18. [23]Anraku Y., Kuwahara H., Fukusato Y., Mizoguchi A., Ishii T., Nitta K., Matsumoto Y., Toh K., Miyata K., Uchida S., Nishina K., Osada K., Itaka K., Nishiyama N., Mizusawa H., Yamasoba T., Yokota T., Kataoka K., Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain. Nat. Commun. 8, 1001 (2017). 29042554 PMC5645389
  19. [24]Huang J.-L., Jiang G., Song Q.-X., Gu X., Hu M., Wang X.-L., Song H.-H., Chen L.-P., Lin Y.-Y., Jiang D., Chen J., Feng J.-F., Qiu Y.-M., Jiang J.-Y., Jiang X.-G., Chen H.-Z., Gao X.-L., Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis. Nat. Commun. 8, 15144 (2017). 28489075 PMC5436231
  20. [25]Hrkach J., Von Hoff D., Ali M. M., Andrianova E., Auer J., Campbell T., De Witt D., Figa M., Figueiredo M., Horhota A., Low S., McDonnell K., Peeke E., Retnarajan B., Sabnis A., Schnipper E., Song J. J., Song Y. H., Summa J., Tompsett D., Troiano G., Van Geen Hoven T., Wright J., LoRusso P., Kantoff P. W., Bander N. H., Sweeney C., Farokhzad O. C., Langer R., Zale S., Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differenciated pharmacological profile. Sci. Transl. Med. 4, 128ra39 (2012). 22491949
  21. [26]McHugh K. J., Nguyen T. D., Linehan A. R., Yang D., Behrens A. M., Rose S., Tochka Z. L., Tzeng S. Y., Norman J. J., Anselmo A. C., Xu X., Tomasic S., Taylor M. A., Lu J., Guarecuco R., Langer R., Jaklenec A., Fabrication of fillable microparticles and other complex 3D microstructures. Science 357, 1138– 1142 (2017). 28912242 PMC6510330
  22. [27]Kondo A., Shahpasand K., Mannix R., Qiu J., Moncaster J., Chen C.-H., Yao Y., Lin Y.-M., Driver J. A., Sun Y., Wei S., Luo M.-L., Albayram O., Huang P., Rotenberg A., Ryo A., Goldstein L. E., Pascual-Leone A., McKee A. C., Meehan W., Zhou X. Z., Lu K. P., Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 523, 431– 436 (2015). 26176913 PMC4718588
  23. [28]Mannix R., Meehan W. P., Mandeville J., Grant P. E., Gray T., Berglass J., Zhang J., Bryant J., Rezaie S., Chung J. Y., Peters N. V., Lee C., Tien L. W., Kaplan D. L., Feany M., Whalen M., Clinical correlates in an experimental model of repetitive mild brain injury. Ann. Neurol. 74, 65– 75 (2013). 23922306 PMC6312716
  24. [29]Suk J. S., Xu Q., Kim N., Hanes J., Ensign L. M., PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99, 28– 51 (2016). 26456916 PMC4798869
  25. [30]Li J., Cai P., Shalviri A., Henderson J. T., He C., Foltz W. D., Prasad P., Brodersen P. M., Chen Y., Costa R. D., Rauth A. M., Wu X. Y., A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood–brain barrier targeting brain metastases of breast cancer. ACS Nano 8, 9925– 9940 (2014). 25307677
  26. [31]Koffie R. M., Farrar C. T., Saidi L.-J., William C. M., Hyman B. T., Spires-Jones T. L., Nanoparticles enhance brain delivery of blood–brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc. Natl. Acad. Sci. U.S.A. 108, 18837– 18842 (2011). 22065785 PMC3219113
  27. [32]M. Naito, T. Yokoyama, K. Hosokawa, K. Nogi, Nanoparticle Technology Handbook (Elsevier, ed. 3, 2018), 471 pp.
  28. [33]Maussang D., Rip J., van Kregten J., van den Heuvel A., van der Pol S., van der Boom B., Reijerkerk A., Chen L., de Boer M., Gaillard P., de Vries H., Glutathione conjugation dose-dependently increases brain-specific liposomal drug delivery in vitro and in vivo. Drug Discov. Today Technol. 20, 59– 69 (2016). 27986226
  29. [34]Rip J., Chen L., Hartman R., van den Heuvel A., Reijerkerk A., van Kregten J., van der Boom B., Appeldoorn C., de Boer M., Maussang D., de Lange E. C. M., Gaillard P. J., Glutathione PEGylated liposomes: Pharmacokinetics and delivery of cargo across the blood–brain barrier in rats. J. Drug Target. 22, 460– 467 (2014). 24524555 PMC4651142
  30. [35]Lam F. C., Morton S. W., Wyckoff J., Han T.-L. V., Hwang M. K., Maffa A., Balkanska-Sinclair E., Yaffe M. B., Floyd S. R., Hammond P. T., Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat. Commun. 9, 1991 (2018). 29777137 PMC5959860
  31. [36]Oller-Salvia B., Sánchez-Navarro M., Giralt E., Teixidó M., Blood–brain barrier shuttle peptides: An emerging paradigm for brain delivery. Chem. Soc. Rev. 45, 4690– 4707 (2016). 27188322
  32. [37]Islam M. A., Xu Y., Tao W., Ubellacker J. M., Lim M., Aum D., Lee G. Y., Zhou K., Zope H., Yu M., Cao W., Oswald J. T., Dinarvand M., Mahmoudi M., Langer R., Kantoff P. W., Farokhzad O. C., Zetter B. R., Shi J., Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat. Biomed. Eng. 2, 850– 864 (2018). 31015614 PMC6486184
  33. [41]Sahay G., Querbes W., Alabi C., Eltoukhy A., Sarkar S., Zurenko C., Karagiannis E., Love K., Chen D., Zoncu R., Buganim Y., Schroeder A., Langer R., Anderson D. G., Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol. 31, 653– 658 (2013). 23792629 PMC3814166
  34. [42]Wu J. P. J., Cheng B., Roffler S. R., Lundy D. J., Yen C. Y. T., Chen P., Lai J. J., Pun S. H., Stayton P. S., Hsieh P. C. H., Reloadable multidrug capturing delivery system for targeted ischemic disease treatment. Sci. Transl. Med. 8, 365ra160 (2016). 27856799
  35. [43]Nance E. A., Woodworth G. F., Sailor K. A., Shih T.-Y., Xu Q., Swaminathan G., Xiang D., Eberhart C., Hanes J., A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci. Transl. Med. 4, 149ra119 (2012). PMC3718558 22932224
  36. [44]Ambruosi A., Khalansky A. S., Yamamoto H., Gelperina S. E., Begley D. J., Kreuter J., Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J. Drug Target. 14, 97– 105 (2006). 16608736
  37. [45]Jaffer H., Adjei I. M., Labhasetwar V., Optical imaging to map blood-brain barrier leakage. Sci. Rep. 3, 3117 (2013). 24178124 PMC3814906
  38. [46]Shahim P., Tegner Y., Wilson D. H., Randall J., Skillbäck T., Pazooki D., Kallberg B., Blennow K., Zetterberg H., Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol. 71, 684– 692 (2014). 24627036
  39. [49]Xu H., Rösler T. W., Carlsson T., de Andrade A., Fiala O., Höllerhage M., Oertel W. H., Goedert M., Aigner A., Höglinger G. U., Tau silencing by siRNA in the P301S mouse model of tauopathy. Curr. Gene Ther. 14, 343– 351 (2014). 25687501
  40. [50]Chiasseu M., Vargas J. L. C., Destroismaisons L., Velde C. V., Leclerc N., Polo A. D., Tau accumulation, altered phosphorylation, and missorting promote neurodegeneration in glaucoma. J. Neurosci. 36, 5785– 5798 (2016). 27225768 PMC6601840
  41. [51]Carron S. F., Alwis D. S., Rajan R., Traumatic brain injury and neuronal functionality changes in sensory cortex. Front. Syst. Neurosci. 10, 47 (2016). 27313514 PMC4889613
  42. [52]Fukuda A. M., Badaut J., siRNA treatment: “A sword-in-the-Stone” for acute brain injuries. Genes 4, 435– 456 (2013). 24705212 PMC3924829
  43. [53]Marklund N., Hillered L., Animal modelling of traumatic brain injury in preclinical drug development: Where do we go from here? Br. J. Pharmacol. 164, 1207– 1229 (2011). 21175576 PMC3229758
  44. [54]Calcul L., Zhang B., Jinwal U. K., Dickey C. A., Baker B. J., Natural products as a rich source of tau-targeting drugs for Alzheimer’s disease. Future Med. Chem. 4, 1751– 1761 (2012). 22924511 PMC3575183
  45. [55]Siahaan A. M. P., Japardi I., Rambe A. S., Indharty R. S., Ichwan M., Turmeric extract supplementation reduces Tau protein level in repetitive traumatic brain injury model. J. Med. Sci. 6, 1953– 1958 (2018). PMC6290398 30559842
  46. [56]Zheng C., Ma C., Bai E., Yang K., Xu R., Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma. Int. J. Clin. Exp. Med. 8, 1658– 1668 (2015). 25932094 PMC4402741
  47. [57]Liu H., Moynihan K. D., Zheng Y., Szeto G. L., Li A. V., Huang B., Egeren D. S. V., Park C., Irvine D. J., Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519– 522 (2014). 24531764 PMC4069155
  48. [58]Xu X., Xie K., Zhang X.-Q., Pridgen E. M., Park G. Y., Cui D. S., Shi J., Wu J., Kantoff P. W., Lippard S. J., Langer R., Walker G. C., Farokhzad O. C., Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc. Natl. Acad. Sci. U.S.A. 110, 18638– 18643 (2013). 24167294 PMC3832000
  49. [59]Robertson R. T., Levine S. T., Haynes S. M., Gutierrez P., Baratta J. L., Tan Z., Longmuir K. J., Use of labeled tomato lectin for imaging vasculature structures. Histochem. Cell Biol. 143, 225– 234 (2015). 25534591

Cited by

Sorted by citations

Authors
Li, W., Qiu, J., Li, X.-L., Aday, S., Zhang, J., Conley, G., Xu, J., Joseph, J., Lan, H., Langer, R., Mannix, R., Karp, J. M., & Joshi, N.
Affiliations
  • Brigham and Women's Hospital (US)
  • Boston Children's Hospital (US)
  • Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA.
  • Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Broad Institute (US)
Corresponding author
  • Mannix, Rebekah
  • Karp, Jeffrey M.
  • Joshi, Nitin
ORCID
Venue
Science Advances
Publisher
American Association for the Advancement of Science (AAAS)
Published
2021-01
Volume
7
Issue
1
ISSN
2375-2548 (ISSN-L)
DOI
10.1126/sciadv.abd6889
PMC
PMC7775748
OpenAlex
W3118611693
Cited by
160
References
9
Citations by year
2026: 13 · 2025: 37 · 2024: 39 · 2023: 26 · 2022: 37 · 2021: 8
FWCI
8.63
Type
journal article
Language
en
Open access
Licence
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders
  • National Institutes of Health (HL095722)
  • Fundação para a Ciência e a Tecnologia (MIT-Portugal-TB/ECE/0013/2013)
  • Harvard Football Players Health Study
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
traumatic brain injury, siRNA delivery, blood-brain barrier, nanoparticle drug delivery, blood-brain barrier permeability, surface chemistry, coating density, PEGylated nanoparticles, brain accumulation, gene silencing
MeSH terms
Brain Injuries, Traumatic, Animals, Blood-Brain Barrier, Brain, RNA, Small Interfering, Mice, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review